Program News
News and stories about members of the UNC Lineberger Cancer Cell Biology Research Program
-
Synthetic lymph node brings new fight to cancer care
A dime-sized technology could transform CAR-T therapy by creating a simpler, more affordable procedure that targets many cancer types and can be done at almost any hospital.
-
UNC Lineberger researchers among world’s most influential in Clarivate 2025 Highly Cited Researchers list
Eleven UNC Lineberger Comprehensive Cancer Center members were named as 2025 Highly Cited Researchers by Clarivate for publishing some of the most influential scientific papers during the past decade.
-
Priming the pump for new cancer treatments
UNC Eshelman School of Pharmacy’s Chemical Biology and Medicinal Chemistry Division is a central hub for cancer therapeutics. Its faculty members are studying the chemical and biological mechanisms that promote cancer growth and persistence.
-
UNC researchers unlock new way to help fight skin cancer
Researchers found that inhibiting a problematic protein in the body helps immunotherapies and CAR-T therapy to better fight off melanoma.
-
UNC Lineberger faculty members presenting Het Talks during University Research Week
Three UNC Lineberger members will share their research during the Het Talks at UNC-Chapel Hill’s University Research Week, Oct. 20-24.
-
UNC honors three cancer center members with 2025 Hettleman Prizes
Sarah Cohen, PhD, Marissa Hall, PhD, and Lindsey James, PhD, were awarded Hettleman Prizes, which recognizes UNC-Chapel Hill early-career faculty who exemplify groundbreaking and innovative research.
-
UNC researchers discover an enzyme that protects DNA during rapid cell divisions
Michael Emanuele, PhD, and colleagues have discovered that an enzyme called USP37 plays a crucial role in ensuring our cells copy their DNA correctly.
-
Five UNC Lineberger members named distinguished professors
Five cancer center members were named distinguished professors, an honor recognizing those who exemplify the highest standards of UNC through their scholarly achievement, teaching excellence and service.
-
Jeremy Rich, MD, MHS, MBA, appointed deputy director of research and chief scientific officer
Jeremy Rich, MD, MHS, MBA, is a board-certified neuro-oncologist specializing in the multidisciplinary care of patients with advanced brain tumors. He is the inaugural Deputy Director of Research and Chief Scientific Officer at UNC Lineberger.
-
Goldstein elected to the American Academy of Arts and Sciences
Bob Goldstein, PhD, has been elected to the American Academy of Arts and Sciences, an honorary society that recognizes the outstanding achievements of individuals in academia, the arts, business, government and public affairs.